New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
05:32 EDTGILDGilead announces results from study of Sovaldi
Gilead Sciences announced results from an open-label clinical trial evaluating once-daily Sovaldi 400 mg tablets for the retreatment of chronic hepatitis C virus, or HCV, infection among patients who failed prior therapy. In Study GS-US-334-0109, patients with genotype 1 HCV infection received 12 weeks of treatment with once-daily Sovaldi plus weight-based ribavirin, or RBV, twice-daily and pegylated interferon. Patients in the study had failed prior regimens containing peg-IFN, RBV and an investigational NS3 protease inhibitor, with or without investigational direct-acting antivirals, or DAAs. 45% of patients had received more than one course of prior therapy, and 90 percent had at least one viral mutation associated with HCV NS3, NS5A or NS5B drug resistance. Among the 50 patients for whom sustained virologic response data was available 12 weeks after the end of treatment, 74% achieved SVR12. Additionally, 80% of patients with baseline resistance against two or more DAAs achieved SVR12. Sovaldi was well tolerated in Study GS-US-334-0109. The most common adverse events were consistent with the safety profiles of peg-IFN and/or RBV.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
July 24, 2014
09:10 EDTGILDGilead price target raised to $165 from $123 at BMO Capital
BMO Capital increased its price target on Gilead after the company reported stronger than expected Q2 results. The firm sees significant near-term growth opportunities and long-term sustainability for Gilead's HCV franchise. It keeps an Outperform rating on the shares.
07:55 EDTGILDGilead valuation still appears compelling, says Wells Fargo
After Gilead reported stronger than expected results, Wells Fargo remains upbeat on the outlook for the company's Sovaldi drug. The firm continues to believe that concerns about Sovaldi's pricing will wane into next year. Wells keeps an Outperform rating on the shares.
07:25 EDTGILDGilead price target raised to $109 from $99 at Leerink
Subscribe for More Information
07:21 EDTGILDGilead removed from short-term buy list at Deutsche Bank
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; YHOO GILD
Subscribe for More Information
05:37 EDTGILDGilead announces new agreement with MPP
Subscribe for More Information
July 23, 2014
16:13 EDTGILDGilead raises FY14 net product sales guidance to $21B-$23B from $11.3B-$11.5B
Subscribe for More Information
16:09 EDTGILDGilead reports Q2 product revenue $6.41B vs. $2.66B last year
Reports Q2 Royalty, contract, and other revenues $122M vs. 110.1M last year. John C. Martin, PhD, Gilead’s chairman and CEO stated, “During Q2, Gilead continued to make significant progress led by strong Sovaldi sales. Since December’s launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical community’s recognition of the benefits of this product. We look forward to making Sovaldi available in additional countries.”
16:05 EDTGILDGilead reports Q2 EPS $2.36, consensus $1.79
Subscribe for More Information
16:01 EDTGILDGilead trading halted, pending news
Subscribe for More Information
16:00 EDTGILDOptions Update; July 23, 2014
iPath S&P 500 VIX Short-Term Futures up 23c to 28.17. Option volume leaders: AAPL FB C GILD MSFT PBR NFLX AMZN TWTR TSLA according to Track Data
15:43 EDTGILDGilead July weekly 90 straddle priced for 5.5% move into Q2
Subscribe for More Information
15:30 EDTGILDNotable companies reporting after market close
Subscribe for More Information
11:40 EDTGILDFDA approves Zydelig for three types of blood cancers
Subscribe for More Information
July 22, 2014
06:14 EDTGILDGilead July weekly volatility elevated into Q2
Subscribe for More Information
July 21, 2014
16:00 EDTGILDOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
09:38 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTGILDGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
12:46 EDTGILDGilead drug cocktail helps treat HIV/HCV-coinfected patients, JAMA says
Subscribe for More Information
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use